{"id":15691,"date":"2023-07-28T14:01:00","date_gmt":"2023-07-28T06:01:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15691"},"modified":"2024-11-29T14:04:15","modified_gmt":"2024-11-29T06:04:15","slug":"eli-lillys-donanemab-shows-significant-slowdown-in-alzheimers-disease-progression-in-phase-iii-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15691","title":{"rendered":"Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study"},"content":{"rendered":"\n

US pharmaceutical major Eli Lilly and Company (NYSE: LLY<\/a>) has revealed the complete results of the Phase III TRAILBLAZER-ALZ 2 study for donanemab, demonstrating that the drug significantly slowed cognitive and functional decline in patients with early symptomatic Alzheimer’s disease (AD).<\/p>\n\n\n\n

Donanemab’s Efficacy in Early Symptomatic Alzheimer’s Disease<\/strong>
The study showed that donanemab significantly slowed cognitive and functional decline for amyloid-positive early symptomatic Alzheimer’s disease patients, reducing their risk of disease progression. Nearly half of the participants at an earlier stage of the disease on donanemab had no clinical progression at one year. Subpopulation analyses revealed that participants at the earliest stage of the disease experienced even greater benefits, with a 60% slowing of decline compared to placebo. The treatment effect continued to increase relative to placebo over the course of the trial, supporting the potential for limited duration dosing. The FDA submission was completed in Q2, with regulatory action expected by the end of the year.<\/p>\n\n\n\n

Design and Outcomes of the TRAILBLAZER-ALZ 2 Study<\/strong>
The double-blind, placebo-controlled Phase III study aimed to evaluate the safety and efficacy of donanemab in participants aged 60-85 years with early symptomatic Alzheimer’s disease (mild cognitive impairment or mild dementia due to Alzheimer’s disease) and confirmed Alzheimer’s disease neuropathology. The study enrolled 1736 participants across eight countries, selected based on cognitive assessments in conjunction with amyloid plaque imaging and tau staging by PET imaging. Treatment with donanemab reduced amyloid plaque on average by 84% at 18 months, compared with a 1% decrease for participants on placebo. Participants were able to discontinue donanemab once they achieved pre-defined criteria of amyloid plaque clearance.<\/p>\n\n\n\n

Ongoing Clinical Trials for Donanemab<\/strong>
Eli Lilly continues to investigate donanemab in multiple clinical trials. These include the TRAILBLAZER-ALZ 3, which focuses on preventing symptomatic Alzheimer’s disease in participants with preclinical AD; the TRAILBLAZER-ALZ 5, a registration trial for early symptomatic Alzheimer’s disease currently enrolling in China; and the TRAILBLAZER-ALZ 6, which aims to expand understanding of ARIA through novel MRI sequences, blood-based biomarkers, and different dosing regimens of donanemab.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[87,17,199,911],"class_list":["post-15691","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-chronic-disease","tag-clinical-trial-results","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"\nEli Lilly's Donanemab Shows Significant Slowdown in Alzheimer's Disease Progression in Phase III Study - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of the Phase III TRAILBLAZER-ALZ 2 study for donanemab, demonstrating that the drug significantly slowed cognitive and functional decline in patients with early symptomatic Alzheimer's disease (AD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15691\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly's Donanemab Shows Significant Slowdown in Alzheimer's Disease Progression in Phase III Study\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15691\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-28T06:01:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-29T06:04:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15691#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15691\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study\",\"datePublished\":\"2023-07-28T06:01:00+00:00\",\"dateModified\":\"2024-11-29T06:04:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15691\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Chronic disease\",\"Clinical trial results\",\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15691#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15691\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15691\",\"name\":\"Eli Lilly's Donanemab Shows Significant Slowdown in Alzheimer's Disease Progression in Phase III Study - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-28T06:01:00+00:00\",\"dateModified\":\"2024-11-29T06:04:15+00:00\",\"description\":\"US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of the Phase III TRAILBLAZER-ALZ 2 study for donanemab, demonstrating that the drug significantly slowed cognitive and functional decline in patients with early symptomatic Alzheimer's disease (AD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15691#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15691\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15691#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Donanemab Shows Significant Slowdown in Alzheimer's Disease Progression in Phase III Study - Insight, China's Pharmaceutical Industry","description":"US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of the Phase III TRAILBLAZER-ALZ 2 study for donanemab, demonstrating that the drug significantly slowed cognitive and functional decline in patients with early symptomatic Alzheimer's disease (AD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15691","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Donanemab Shows Significant Slowdown in Alzheimer's Disease Progression in Phase III Study","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15691","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-28T06:01:00+00:00","article_modified_time":"2024-11-29T06:04:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15691#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15691"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study","datePublished":"2023-07-28T06:01:00+00:00","dateModified":"2024-11-29T06:04:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15691"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Chronic disease","Clinical trial results","Eli Lilly","NYSE: LLY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15691#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15691","url":"https:\/\/flcube.com\/?p=15691","name":"Eli Lilly's Donanemab Shows Significant Slowdown in Alzheimer's Disease Progression in Phase III Study - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-28T06:01:00+00:00","dateModified":"2024-11-29T06:04:15+00:00","description":"US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of the Phase III TRAILBLAZER-ALZ 2 study for donanemab, demonstrating that the drug significantly slowed cognitive and functional decline in patients with early symptomatic Alzheimer's disease (AD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15691#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15691"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15691#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15691"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15691\/revisions"}],"predecessor-version":[{"id":15692,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15691\/revisions\/15692"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}